following an abbreviated submission:
glecaprevir/pibrentasvir (Maviret®) is accepted for use within NHSScotland.
Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years.
SMC has previously accepted glecaprevir/pibrentasvir for the treatment of chronic HCV infection in adults.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir/pibrentasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice364KB (PDF)
- Medicine name:
- glecaprevir/pibrentasvir (Maviret)
- SMC ID:
For treatment of chronic hepatitis C virus (HCV) infection in adults and in adolescents aged 12 to <18 years.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Submission type
- Date advice published:
- 11 November 2019